Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLAG3-IL2
- Development stage
- Preclinical
- Lead developer
- Bonum Therapeutics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CLAG3-IL2 is a conditionally active immunocytokine designed to selectively deliver interleukin-2 (IL-2) activity to LAG-3-expressing antigen-experienced T cells. It is built using a dual-binding antibody (DBA) platform that enables the molecule to remain inactive in the periphery and only activate IL-2 signaling upon binding to LAG-3 on target T cells. This approach aims to expand and activate tumor-specific CD8+ T cells within the tumor microenvironment while minimizing peripheral activation of IL-2 receptor-positive natural killer (NK) or T cell populations, thereby reducing systemic toxicity commonly associated with traditional IL-2 therapies. Preclinical studies demonstrate that CLAG3-IL2 inhibits tumor growth without inducing typical IL-2 toxicities even at high doses and exhibits monoclonal antibody-like pharmacokinetics[1][2][5]. The drug is being developed primarily for cancer immunotherapy by Bonum Therapeutics[4][5].
- Brand names
- cLAG3-IL2cLAG-3-IL2cLAG 3-IL2
- Other names
- cLAG3-IL2cLAG-3-IL2cLAG 3-IL2
02
Targets
IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on CLAG3-IL2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLAG3-IL2.